WHO ICTRP trial
The effects of memantine versus placebo on visual functions of patient with…
ACTRN12611000350921 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12611000350921 |
|---|---|
| Public title | The effects of memantine versus placebo on visual functions of patient with optic neuritis |
| Scientific title | In patients with optic neuritis, is Memantine as good as or better than placebo for improving visual functions? |
| Primary sponsor | Tehran University of Medical sciences |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 / Phase 3 |
| Countries | Iran, Islamic Republic Of |
| Conditions | isolated optic neuritis;optic neuritis; isolated optic neuritis optic neuritis;Eye - Diseases / disorders of the eye |
| Interventions | Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks) |
| Registration date | May 4, 2011 |
| Target size | 60 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: